% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Bruer:284335,
      author       = {Bräuer, Stefan and Sondermann, Verena and Schniewind,
                      Inaki and Hähnel, Tom and Dinter, Elisabeth and Kleineidam,
                      Luca and Stark, Melina and Schmid, Matthias and Sodenkamp,
                      Sebastian and Laske, Christoph and Spruth, Eike and Priller,
                      Josef and Janowitz, Daniel and Bürger, Katharina and
                      Kilimann, Ingo and Teipel, Stefan and Storch, Alexander and
                      Hansen, Niels and Wiltfang, Jens and Glanz, Wenzel and
                      Düzel, Emrah and Preis, Lukas and Peters, Oliver and
                      Hellmann-Regen, Julian and Wagner, Michael and Bernhardt,
                      Alexander Maximilian and Levin, Johannes and Petzold, Gabor
                      and Kronmüller, Marie and Gamez, Anna and Spottke, Annika
                      and Brosseron, Frederic and Rostamzadeh, Ayda and Jessen,
                      Frank and Hermann, Andreas and Fliessbach, Klaus and
                      Schneider, Anja and Falkenburger, Björn H},
      title        = {{A}lpha-synuclein quantitative seed amplification assay
                      predicts conversion to dementia.},
      journal      = {Alzheimer's and dementia},
      volume       = {22},
      number       = {1},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2026-00110},
      pages        = {e71167},
      year         = {2026},
      abstract     = {The alpha-synuclein seed amplification assay (SAA) has
                      shown excellent performance in the detection of Lewy body
                      pathology in cerebrospinal fluid (CSF). Lewy body pathology
                      is prognostically relevant in patients at risk for dementia.
                      Current assays only provide binary results, so there is a
                      need to quantify the extent of pathology in living
                      patients.In addition to the 'standard' SAA, we developed a
                      quantitative SAA (qnSAA) and measured 432 CSF samples (216
                      baseline-follow-up pairs).qnSAA results correlated with
                      cognitive performance. Seventy-five percent of participants
                      with fast qnSAA kinetics converted to dementia in the
                      observed interval. Overall, participants with fast qnSAA
                      kinetics accounted for $27.3\%$ of dementia converters in
                      the entire cohort.Findings demonstrate promising properties
                      of qnSAA measurements in a cohort of patients at risk for
                      dementia. qnSAA results showed improved prognostic relevance
                      and have potential to measure target engagement of therapies
                      against Lewy body pathology.},
      keywords     = {Humans / alpha-Synuclein: cerebrospinal fluid / Male /
                      Female / Dementia: cerebrospinal fluid / Dementia: diagnosis
                      / Aged / Disease Progression / Biomarkers: cerebrospinal
                      fluid / Aged, 80 and over / Lewy Body Disease: cerebrospinal
                      fluid / Prognosis / Cohort Studies / Alzheimer´s disease
                      (Other) / Lewy body (Other) / alpha‐synuclein (Other) /
                      dementia (Other) / real‐time quaking‐induced conversion
                      (Other) / seed amplification assay (Other) / alpha-Synuclein
                      (NLM Chemicals) / Biomarkers (NLM Chemicals)},
      cin          = {AG Falkenburger / AG Wagner / AG Schmid Bonn / ICRU / AG
                      Gasser / AG Priller / Clinical Research (Munich) / AG Teipel
                      / AG Storch / AG Wiltfang / AG Düzel / AG Peters / AG
                      Endres / AG Levin / AG Petzold / AG Spottke / AG Heneka / AG
                      Jessen / AG Hermann / Patient Studies (Bonn) / AG Schneider},
      ddc          = {610},
      cid          = {I:(DE-2719)1710012 / I:(DE-2719)1011201 /
                      I:(DE-2719)1013028 / I:(DE-2719)1240005 / I:(DE-2719)1210000
                      / I:(DE-2719)5000007 / I:(DE-2719)1111015 /
                      I:(DE-2719)1510100 / I:(DE-2719)5000014 / I:(DE-2719)1410006
                      / I:(DE-2719)5000006 / I:(DE-2719)5000000 /
                      I:(DE-2719)1811005 / I:(DE-2719)1111016 / I:(DE-2719)1013020
                      / I:(DE-2719)1011103 / I:(DE-2719)1011303 /
                      I:(DE-2719)1011102 / I:(DE-2719)1511100 / I:(DE-2719)1011101
                      / I:(DE-2719)1011305},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41572624},
      pmc          = {pmc:PMC12828062},
      doi          = {10.1002/alz.71167},
      url          = {https://pub.dzne.de/record/284335},
}